Dexamethasone opthalmic - Oculis Pharma

Drug Profile

Dexamethasone opthalmic - Oculis Pharma

Alternative Names: dexamethasone cyclodextrin nanoparticle eye drops; dexamethasone/γCD nanoparticle; DexNP; OC-118

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oculis Pharma
  • Developer Oculis Pharma; Tel Aviv University
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic macular oedema; Glaucoma; Postoperative inflammation; Uveitis

Most Recent Events

  • 10 Aug 2017 Chemical structure information added
  • 05 Jul 2017 Phase-II clinical trials in Diabetic macular oedema (In adults, In the elderly) in Denmark (Ophthalmic) (EudraCT2017-001172-36)
  • 31 Aug 2016 Oculis Pharma has patent protection for its nanoparticle technology in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top